Endsulin, Inc.

Endsulin, Inc. is a pre-clinical stage biotechnology company focused on developing a revolutionary liver-directed gene therapy to treat Type 1 Diabetes (T1DM). Its mission is to end insulin dependence for good and free patients from being defined by diabetes by delivering a patented genetic factor to the liver, restoring the body’s own ability to produce and regulate insulin.